US EditionBATF2: A novel tumor suppressor silenced by glutamine in head and neck cancer
Glutamine silences BATF2 in head and neck tumors, reducing immune response; inhibiting glutamine metabolism restored immunity in five preclinical models, MD Anderson researchers found.
3 Articles
3 Articles
High glutamine levels suppress immune response in head and neck cancer tumors
A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
BATF2: A novel tumor suppressor silenced by glutamine in head and neck cancer
A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
High Levels of Protein Drive Tumor Immune Suppression in Head and Neck Cancer
* BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment * Glutamine silences BATF2 and leads to a weakened immune response * Blocking glutamine reverses these effects, increasing BATF2 expression and improving overall immunity
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
